Medicine and Dentistry
ABVD
26%
Adverse Event
21%
Arm
17%
Autologous Stem Cell Transplantation
14%
B Cell
11%
B-Cell Lymphoma
11%
Bleomycin
13%
Breast Cancer
14%
Brentuximab Vedotin
34%
Cancer Research
13%
Classical Hodgkin Lymphoma
28%
Clinical Feature
8%
Cyclophosphamide
14%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
17%
Dacarbazine
14%
Diffuse Large B-Cell Lymphoma
61%
Disease Exacerbation
9%
Diseases
53%
Doxorubicin
38%
Etoposide
10%
Event Free Survival
10%
Follicular Lymphoma
31%
Hazard Ratio
9%
High Dose Chemotherapy
9%
Hodgkin's Lymphoma
100%
Ibrutinib
15%
Interstitial Cell
8%
Lenalidomide
13%
Loncastuximab Tesirine
9%
Malignant Neoplasm
15%
MALT Lymphoma
9%
Mantle Cell Lymphoma
18%
Neoplasm
80%
Non-Hodgkin Lymphoma
39%
Overall Survival
46%
Peripheral T-Cell Lymphoma
10%
Positron Emission Tomography
14%
Prednisolone
10%
Prognostic Factor
19%
Progression Free Survival
46%
Radiation Therapy
31%
Reproducibility
32%
Rituximab
32%
Sensitivity and Specificity
32%
Student T Test
32%
Subgroup Analysis
9%
T Cell
10%
Tositumomab
8%
Vinblastine
22%
Vincristine
15%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
18%
Anthracycline
9%
B Cell Lymphoma
8%
Biological Marker
8%
Bleomycin
13%
Brentuximab Vedotin
30%
Chemotherapy
66%
Classical Hodgkin Lymphoma
19%
Cohort Study
7%
Comorbidity
7%
Cyclophosphamide
18%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
13%
Dacarbazine
12%
Diffuse Large B Cell Lymphoma
47%
Disease
41%
Disease Exacerbation
9%
Doxorubicin
37%
Etoposide
16%
Event Free Survival
13%
Follicular Lymphoma
29%
High Dose Chemotherapy
9%
Hodgkin Disease
58%
Ibritumomab Tiuxetan
6%
Ibrutinib
13%
Ifosfamide
11%
Iodine-131
8%
Lenalidomide
11%
Loncastuximab Tesirine
13%
Malignant Neoplasm
20%
Mantle Cell Lymphoma
16%
Monotherapy
10%
Neoplasm
7%
Neutropenia
8%
Nonhodgkin Lymphoma
28%
Ofatumumab
8%
Osteosarcoma
6%
Overall Survival
35%
Phase II Trials
7%
Prednisolone
9%
Progression Free Survival
42%
Remission
18%
Rituximab
39%
Second Cancer
8%
Small Cell Lung Cancer
11%
Soft Tissue Sarcoma
8%
Tolerability
12%
Tositumomab
8%
Tositumomab I 131
6%
Vinblastine
16%
Vincristine
20%